Enanta Pharmaceuticals (NASDAQ:ENTA) Now Covered by Rodman & Renshaw

Rodman & Renshaw initiated coverage on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) in a research report released on Thursday, MarketBeat.com reports. The firm issued a buy rating and a $20.00 target price on the biotechnology company’s stock.

Several other research analysts also recently issued reports on ENTA. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, February 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Wednesday, January 21st. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Enanta Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $20.29.

Enanta Pharmaceuticals Stock Up 2.8%

NASDAQ:ENTA opened at $12.51 on Thursday. Enanta Pharmaceuticals has a 12 month low of $4.09 and a 12 month high of $17.15. The company’s 50 day moving average is $13.43 and its 200-day moving average is $12.59. The firm has a market cap of $363.04 million, a price-to-earnings ratio of -3.91 and a beta of 0.96.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, February 9th. The biotechnology company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.12. The firm had revenue of $18.62 million for the quarter, compared to the consensus estimate of $16.14 million. Enanta Pharmaceuticals had a negative net margin of 106.80% and a negative return on equity of 78.58%. Research analysts predict that Enanta Pharmaceuticals will post -4.65 EPS for the current fiscal year.

Institutional Trading of Enanta Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ENTA. Seven Fleet Capital Management LP acquired a new stake in shares of Enanta Pharmaceuticals during the fourth quarter worth $36,000. Virtu Financial LLC bought a new stake in shares of Enanta Pharmaceuticals during the fourth quarter worth $220,000. Invesco Ltd. raised its stake in shares of Enanta Pharmaceuticals by 325.2% in the 4th quarter. Invesco Ltd. now owns 253,811 shares of the biotechnology company’s stock valued at $4,003,000 after purchasing an additional 194,113 shares during the period. Krensavage Asset Management LLC raised its position in Enanta Pharmaceuticals by 30.8% in the 4th quarter. Krensavage Asset Management LLC now owns 2,766,390 shares of the biotechnology company’s stock valued at $43,626,000 after buying an additional 651,946 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new stake in shares of Enanta Pharmaceuticals in the fourth quarter valued at approximately $997,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.